Moura, David S. http://orcid.org/0000-0002-6514-2419
Mondaza-Hernandez, Jose L.
Sanchez-Bustos, Paloma
Peña-Chilet, Maria
Cordero-Varela, Juan A.
Lopez-Alvarez, Maria
Carrillo-Garcia, Jaime
Martin-Ruiz, Marta
Romero-Gonzalez, Pablo
Renshaw-Calderon, Marta
Ramos, Rafael
Marcilla, David
Alvarez-Alegret, Ramiro
Agra-Pujol, Carolina
Izquierdo, Francisco
Ortega-Medina, Luis
Martin-Davila, Francisco
Hernandez-Leon, Carmen Nieves
Romagosa, Cleofe
Salgado, Maria Angeles Vaz
Lavernia, Javier
Bagué, Silvia
Mayodormo-Aranda, Empar
Alvarez, Rosa
Valverde, Claudia
Martinez-Trufero, Javier
Castilla-Ramirez, Carolina
Gutierrez, Antonio
Dopazo, Joaquin
Hindi, Nadia
Garcia-Foncillas, Jesus
Martin-Broto, Javier http://orcid.org/0000-0001-7350-6916
Funding for this research was provided by:
GEIS (GEIS-38)
Pharmamar
Article History
Received: 20 November 2023
Revised: 10 April 2024
Accepted: 22 April 2024
First Online: 17 May 2024
Declarations
:
: David S. Moura reports institutional research grants from PharmaMar, Eisai, Immix BioPharma, and Novartis outside the submitted work; travel support from PharmaMar, Eisai, Celgene, Bayer, and Pfizer. Nadia Hindi reports grants, personal fees and non-financial support from PharmaMar, personal fees from Lilly, grants from Eisai, and Novartis, outside the submitted work and research funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GSK, Novartis, Blueprint, Nektar, Forma, Amgen and Daichii-Sankyo. Javier Martin-Broto reports research grants from PharmaMar, Eisai, Immix BioPharma, and Novartis outside the submitted work; honoraria for advisory board participation and expert testimony from PharmaMar, Eli Lilly and Company, Bayer, GSK, Novartis, Boehringer Ingelheim, Amgen, Roche, Tecnofarma and Asofarma; and research funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, BMS, Pfizer, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GSK, Celgene, Novartis, Blueprint, Adaptinmune, Nektar, Forma, Amgen, Daichii-Sankyo, Ran Therapeutics, INHIBRX, Ayala Pharmaceuticals, Philogen, Cebiotex, PTC Therapeutics, Inc. and SpringWorks therapeutics. The other authors declare no potential conflicts of interest.
: The observational study protocol was approved by the Ethics Committees and the institutional review board of the university hospitals Virgen del Rocio and Virgen de la Macarena, Seville, Spain. The in vivo experiments were approved by the Institutional Committee of Animal Research (Ethics committee of the university hospitals Virgen del Rocio and Virgen de la Macarena, Seville, Spain).
: Not applicable.
: Not applicable.